Progress in clinical treatment of multiple sclerosis and neuromyelitis optica spectrum disorders

VernacularTitle:多发性硬化与视神经脊髓炎谱系疾病的临床治疗进展
Author: Daiqiang LIU ¹ ; Yanlei HAO
Author Information

1. 272000,山东省济宁医学院研究生院
Keywords: Multiple sclerosis/TH; Neuromyelitis optica/TH; Review
From: Journal of Chinese Physician 2018;20(8):1260-1266
CountryChina
Language:Chinese
Abstract: Both multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSDs)are the most common demyelinating diseases of the Central Nervous System.Hormone,intravenous immunoglobulin and plasma exchange seem to be an effective therapy during MS and NMOSD acute phase;however,immunomodulators and immunosuppressive agents are conventional treatments for MS in the remission period,in addition monoclonal antibody,intravenous immunoglobulin G,estrogen,statins,vaccination and traditional Chinese medicine have also been gradually applied to clinical practice.Combined maintenance therapy with low-dose hormones and immunosuppressive agents will benefit NMOSD patients.Because of the different pathogenesis,MS and NMOSD have obvious differences in treatment.This review mainly focus on progress in clinical treatment of multiple sclerosis and neuromyelitis optica spectrum disorders.